RedHill Biopharma’s bowel syndrome drug data fails to impress investors

Story image for Drug from Kaiser Health NewsRedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower.

The company said the drug, Bekinda, improved stool consistency in patients when compared with a placebo. The drug, however, did not show statistical significance in improving abdominal pain and overall response in patients – secondary goals in the study.

U.S.-listed shares of the Tel Aviv-based company are down about 11.2 percent at $9.60 in late morning trade.

“The study was not designed or meant to show significance in the secondary endpoints … the results are actually good according to the small sample size,” RedHill’s Chief Executive Dror Ben-Asher told Reuters.

The trial was testing a 12-mg dose – a once-daily oral pill formulation of a 5-HT3 receptor antagonist called ondansetron – in 126 patients over 18 years of age.

Receptor antagonists such as 5-HT3 are a class of drugs known to slow intestinal movement in patients.

The U.S Food and Drug Administration has already approved a different kind of 5-HT3 antagonist called Lotronex in the United States to treat women with IBS-D.

Other drugs to treat IBS-D in both men and women include Valeant Pharmaceuticals International Inc’s Xifaxan and Allergan Plc’s Viberzi.

RedHill told Reuters it expects to start a late-stage trial on Bekinda by late 2018.

Irritable bowel syndrome is a chronic condition that affects up to 30 million people in the United States, out of which over 50 percent cases belong to IBS-D, the company said.

The disease has two other forms: constipation (IBS-C) and mixed (IBS-M).

RedHill is also testing Bekinda to treat acute gastroenteritis and gastritis, an inflammation of the stomach and intestines that causes vomiting and diarrhea.

In June, RedHill reported positive results from a late-stage trial testing the drug in patients with gastroenteritis

[“Source-timesofindia”]

  • Article By :
    I am a blogger with the main motive of writing articles at my choice of level. I do love to write articles and keep my website updated regularly , if you love my article then be sure to share with your friends as they would love to read my article...

Random Posts